This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Peterson, E. D. Search for Related Content PubMed PubMed Citation Articles by Peterson, E. D.

Early use of glycoprotein IIb/IIIa inhibitors in non–ST-elevation acute myocardial infarction

Observations from the National Registry of Myocardial Infarction 4

Eric D. Peterson, MD, MPH^*,*, Charles V. Pollack, Jr, MD, MA, Matthew T. Roe, MD, MHS^*, Lori S. Parsons, BS, Katherine A. Littrell, PhD, RN, John G. Canto, MD, MSPH, FACC^||, Hal V. Barron, MD National Registry of Myocardial Infarction (NRMI) 4 Investigators

^* Duke Clinical Research Institute, Durham, North Carolina, USA
University of Pennsylvania, Philadelphia, Pennsylvania, USA
Ovation Research, Highland Park, Illinois, USA
Genentech, Inc., San Francisco, California, USA
^|| University of Alabama, Birmingham, Alabama, USA

View larger version (21K): [in a new window]   Figure 1 In-hospital mortality for patients treated with a glycoprotein (GP) IIb/IIIa inhibitor versus those not treated, by the National Registry of Myocardial Infarction non–ST-elevation myocardial infarction (NRMI-NSTEMI) risk score.

View larger version (19K): [in a new window]   Figure 2 Unadjusted and risk-adjusted in-hospital mortality for patients with non–ST-elevation myocardial infarction (NSTEMI), by the proportion of NSTEMI patients at each hospital treated early with a glycoprotein (GP) IIb/IIIa inhibitor.